Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma

Dickinson, M; Martinez-Lopez, J; Jousseaume, E; Yang, H; Chai, X; Xiang, C; Wang, T; Zhang, J; Ramos, R; Schuster, SJ; Fowler, N

Author(s): Dickinson, M; Martinez-Lopez, J; Jousseaume, E; Yang, H; Chai, X; Xiang, C; Wang, T; Zhang, J; Ramos, R; Schuster, SJ; Fowler, N;
Details: Publication Year 2024-03,Volume 65,Issue #3,Page 323-332
Journal Title: Leukemia & Lymphoma
Publication Type: Research article
Abstract: Regulatory approvals of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) have established the feasibility of chimeric antigen receptor T-cell therapies for the treatment of adults with relapsed or refractory follicular lymphoma (r/r FL). This study used individual patient data from ELARA (tisa-cel) and aggregate published patient data from ZUMA-5 (axi-cel) to compare efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methods. After adjustment for baseline differences in the trial populations, the results suggested that tisa-cel (n = 52), compared with axi-cel (n = 86), had similar effects on overall response rate (91.2% vs. 94.2%; p = .58), complete response rate (74.0% vs. 79.1%; p = .60), progression-free survival (HR [95% CI]: 0.8 [0.4, 1.9]; p = .67), and overall survival (HR [95% CI]: 0.5 [0.2, 1.5]; p = .21). Tisa-cel (n = 53) was associated with better safety outcomes than axi-cel (n = 124), reflected by lower rates of any grade and grade ≥3 cytokine release syndrome and neurological events.
Publisher: Taylor & Francis
Keywords: Adult; Humans; *Lymphoma, Follicular/therapy; Immunotherapy, Adoptive/adverse effects; *Biological Products/adverse effects; Cytokine Release Syndrome; *Lymphoma, Large B-Cell, Diffuse; Antigens, CD19/adverse effects; *Receptors, Antigen, T-Cell; Relapsed/refractory follicular lymphoma; axicabtagene ciloleucel; matching-adjusted indirect comparison; tisagenlecleucel
Department(s): Clinical Haematology
Publisher's Version: https://doi.org/10.1080/10428194.2023.2289854
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-03-05 04:47:26

Last Modified: 2024-03-05 04:47:58